| Literature DB >> 31388357 |
Sarah Casey1, Sean Lanting1, Christopher Oldmeadow2, Vivienne Chuter1.
Abstract
BACKGROUND: The ankle brachial index (ABI) is widely used in clinical practice as a non-invasive method to detect the presence and severity of peripheral arterial disease (PAD). Current guidelines suggest that it should be used to monitor potential progression of PAD in affected individuals. As such, it is important that the test is reliable when used for repeated measurements, by the same or different health practitioners. This systematic review aims to examine the literature to evaluate the inter- and intra-rater reliability of the ABI.Entities:
Keywords: Ankle brachial index; Lower extremity artery disease; Peripheral arterial disease; Reliability; Repeatability; Reproducibility
Mesh:
Year: 2019 PMID: 31388357 PMCID: PMC6679535 DOI: 10.1186/s13047-019-0350-1
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Search terms: searches were limited to human studies
| Databases: MEDLINE (1946+), EMBASE (1947+), and CINAHL Complete | |
|---|---|
| 1 | Ankle brachial pressure |
| 2 | Ankle arm pressure |
| 3 | Ankle brachial ind* |
| 4 | Reliab* |
| 5 | Consistenc* |
| 6 | Accura* |
| 7 | Reproduc* |
| 8 | Repeat* |
| 9 | Agreement |
| 10 | Precision |
| 11 | 1 or 2 or 3 AND 4 or 5 or 6 or 7 or 8 or 9 or 10 |
Fig. 1PRISMA flow chart
Participant characteristics and reliability measure
| Reference | Number (n) | Gender (M,F) | Age (years) | Height (cm) | Weight (kg) | DM & control | DM duration | Medical history | PAD | Reliability measure |
|---|---|---|---|---|---|---|---|---|---|---|
| Inter-rater reliability ( | ||||||||||
| Aboyans et al. (2008) [ | 54 | 28, 26 | 52.8 ± 17.1 | NR | NR | DM 35.2% control NR | NR | HT 38.9%, DL 38.9%, CAD 33.3% CVD 11.1% TS 22.2%, | 19 IC, 25 RF, 10 healthy | ICC Doppler: Inter: 0.79 (0.70–0.85) Pulse: inter: 0.40 (0.5–0.57) Auto ABI inter: 0.44 (0.27–0.58) |
| Alvaro-Afonso et al. (2018) [ | 21 | 15, 6 | 67 ± 8.7 | NR | NR | All DM2: control NR | NR | HT 19, DL 17, NEU 18, NEP 1, TS 6 | NR | Kappa coefficient Normal: 0.4 (p < 0.001), PAD 0.7 ( |
| Chesbro et al. (2011) [ | 20 | NR | 22–30 | NR | NR | NR | NR | Healthy volunteers only | None | ICC Doppler: R: 1.00 (95%CI 0.999–1.00, |
| Chesbro et al. (2013) [ | 10 | 5, 5 | NR | NR | NR | NR | NR | ‘Healthy young adults’ | None | ICC Vascular Cuff Right: Trial 1: 0.853; Trial 2: 0.898 Left: Trial 1: 0.448; Trial 2: 0.938 Standard Cuff Right: Trial 1: 0.902; Trial 2:0.817 Left: Trial 1: 0.826; Trial 2: 0.867 |
| de Graff et al. (2001) [ | 54 | 31, 23 | 66 ± 12 | NR | NR | DM 36% control NR | NR | HT 43%, Dl 35%, CAD 36%, CVD 20%, | Suspected | Repeatability Coefficient/ICC Inter: day 20 / 0.92 Inter: week 27 / 0.87 |
| Georgakarakos et al. (2013) [ | 18 | 12, 6 | 54–74 | NR | NR | 9 DM: 3 oral, 6 insulin | NR | HT 15, DL 9, TS 4 | All PAD | Mean, Standard Error, t-test PAD: 0.77 ± 0.19, No PAD: 1.37 ± 0.12, Severe PAD: 0.23 ± 0.07, |
| Holland-Letz et al. (2007) [ | 108 | 50, 58 | 68.1 ± 1.5 | NR | BMI 29 ± 4.3 | DM 15.7% control NR | NR | HT 58.1% DL 54.8%, TS 9.2% current, 40.7% ex-, Hx vasc surg 6 subjects | 68.1 ± 1.5 | ICC for inter-observer: 0.423 Inter-ob SD 0.103 |
| Jaffer et al. (2008) [ | 25 | NR | NR | NR | NR | NR | NR | NR | All suspected PAD | Pearson CC |
| Langen et al. (2009) [ | 20 | 11, 9 | 41–75 | NR | NR | NR | NR | NR | All IC Symptoms | Interobserver variability: 10% (SD 0.8) |
| Mätzke et al. (2003) [ | 30 | 18, 15 (no of limbs) | 26 > 65 yrs., 7 ≤ 65 yrs | NR | NR | 8 DM, control NR | NR | NR | Ischaemic pressure lesion or rest pain | Coefficient of variation: 3.2 |
| Span et al. (2016) [ | 136 | NR | 64 ± 7.8 | NR | NR | 19 (14%) control not reported | NR | HT66, DL 58, TS 22 current, 39 ex- | RF or IC | Coefficient of variation Doppler: 5.9% R & L legs Auto: Right 3.2% Left 3.5% |
| Intra-rater reliability ( | ||||||||||
| Aboyans et al. (2008) [ | 54 | 28, 26 | 52.8 ± 17.1 | NR | NR | DM 35.2% control NR | NR | HT 38.9%, DL 38.9%, CAD 33.3% CVD 11.1% TS 22.2%, | 19 IC, 25 RF, 10 healthy | ICC Doppler: Intra: 0.89 (0.84–0.92) Pulse: Intra: 0.60 (0.44–0.73), |
| Chesbro et al. (2013) [ | 10 | 5, 5 | NR | NR | NR | NR | NR | ‘Healthy young adults’ | None | ICC- Intra-rater Vascular Cuff Rater 1 R: 0.750; Rater 1 R: 0.696 Rater 2 R: 0.551; Rater 2 L: 0.869 Standard Cuff Rater 1 R: 0.628; Rater 1 L: 0.420 Rater 2 R: 0.620; Rater 2 L:0.585 |
| de Graff et al. (2001) [ | 54 | 31, 23 | 66 ± 12 | NR | NR | DM 36% control NR | NR | HT 43%, Dl 35%, CAD 36%, CVD 20%, | Suspected | Repeatability Coefficient/ICC Intra: day 9 / 0.98 Intra: week 22 / 0.89 |
| Demir et al. (2016) [ | 161 | 87, 74 | 52.03 ± 18.99 | 165.12 ± 8.88 | 75.61 ± 13.4 | DM NR | NR | HT 62.7%, DL 46.6%, TS 29.8%, | Mixed population | ICC Single measurement 0.808 Mean: 0.927 |
| Faccenda et al. (1988) [ | 36 | 28,8 | 56 ± 11 | NR | NR | All DM1 | NR | No other hx reported | NR | Coefficient of variation 8% |
| Holland-Letz et al. (2007) [ | 108 | 50, 58 | 68.1 ± 1.5 | NR | BMI 29 ± 4.3 | DM 15.7% control NR | NR | HT 58.1% DL 54.8%, TS 9.2% current, 40.7% ex-, Hx vasc surg 6 subjects | 68.1 ± 1.5 | Intra-observer Variance: 0.008, SD 0.87 [0.081; 0.095] |
| Millen et al. (2018) [ | 66 | 51, 15 | 69.5 ± 12 yrs. (range 35–92) | NR | NR | 4 DM1, 14 DM2 | HT 79%, DL 68%, CAD 44%, CVD 17%, TS 15% current, 59% ex- | 36 IC, 4 rest pain | Coefficient of variation: Dopplex Ability: 9.65 ± 12% Parks Flo-lab: 4.95 ± 3% | |
| Rosenbaum et al. (2012) [ | 157 | 80, 77 | 59.1 ± 13.2 | NR | NR | 35 DM, control NR | NR | HT88, DL 103, CAD 14, CVD 2, TS 27 current, 49 ex- | 11 PAD, all RF or IC | Coefficient of variation: Dopplex Ability: 9.65 ± 12% Parks Flo-lab: 4.95 ± 3% |
NR Not reported, DM Diabetes, HT Hypertension, DL Dyslipidaemia, CAD Coronary artery disease, CVD Cerebrovascular disease, NEU Neuropathy, NEP Nephropathy, TS smoking, IC Intermittent claudication, RF risk factors, PAD Peripheral arterial disease
QAREL Checklist
| Item | Aboyans et al. (2008) [ | Alvaro-Afonso et al. (2018) [ | Chesbro et al. (2011) [ | Chesbro et al. (2013) [ | de Graaff et al. 2001) [ | Demir et al. (2016) [ | Faccenda et al. (1988) [ | Georgakarakos et al. (2013) [ | Holland-Letz et al. (2007) [ | Jaffer et al. (2008) [ | Langen et al (2009) [ | Matzke et al. (2003) [ | Millen et al. (2018) [ | Rosenbaum et al. (2012) [ | Span et al. (2016) [ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Was the test evaluated in a sample of subjects who were representative of those to whom the authors intended the results to be applied? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Was the test performed by raters who were representative of those to whom the authors intended the results to be applied? | Y | U | Y | Y | Y | Y | U | Y | Y | Y | Y | Y | Y | Y | Y |
| 3. Were raters blinded to the findings of other raters during the study? | Y | U | Y | Y | Y | NA | NA | Y | U | U | Y | Y | Y | NA | Y |
| 4. Were raters blinded to their own prior findings of the test under evaluation? | Y | NA | U | U | U | U | Y | NA | Y | NA | NA | NA | NA | U | Y |
| 5. Were raters blinded to the results of the reference standard for the target disorder (or variable) being evaluated? | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 6. Were raters blinded to clinical information that was not intended to be provided as part of the testing procedure or study design? | U | U | U | U | U | U | U | U | U | U | U | Y | N | U | U |
| 7. Were raters blinded to additional cues that were not part of the test? | U | U | U | U | U | U | U | U | U | U | U | U | N | U | U |
| 8. Was the order of examination varied? | U | U | Y | Y | U | N | U | U | U | U | N | U | Y | U | U |
| 9. Was the time interval between repeated measurements compatible with the stability (or theoretical stability) of the variable being measured? | U | Y | Y | Y | Y | Y | Y | Y | Y | U | Y | U | Y | U | U |
| 10. Was the test applied correctly and interpreted appropriately? | N | Y | Y | Y | Y | Y | N | Y | N | U | Y | Y | Y | N | Y |
| 11. Were appropriate statistical measures of agreement used? | Y | Y | Y | Y | Y | Y | P | Y | Y | Y | U | N | Y | Y | Y |
Y Yes, N No, U Unclear, P Partly, NA Not applicable